Comprehensive Medical Weight Loss
Weight loss medications, or “Anti-obesity medications,” can not only help you lose weight and keep it off, but can improve your health and your quality of life. There are many categories now – older medications like phentermine and tenuate, and newer ones like Wegovy and Zepbound.
Saxenda, the newest FDA-approved prescription weight loss medication, is now available at retail pharmacies. We are excited to announce the availability of another new and novel treatment to help you lose weight and keep it off permanently.
I am very excited that today the FDA approved a new weight loss drug. Saxenda works differently than the other weight loss medications. It is a GLP-1 receptor agonist. GLP-1 is a hormone released by our small intestines that tells our brains it is time to stop eating. It is one of the important ways that we know to stop eating. Naturally, it is released mostly in response to eating protein and fat, and the process happens about 20 minutes after eating.
This is an exciting year for weight loss medications! Hot on the heels of the FDA approval for Contrave, the FDA is expected to approve Saxenda, another novel weight loss drug soon. Saxenda (liraglutide) is an analog of GLP-1 (glucose-like peptide 1). GLP-1 is a hormone our small intestine makes in response to eating.
Contrave will be available at pharmacies starting October 20th. It is FDA-approved for individuals with a BMI over 30, or over 27 with a weight-related health problem like high cholesterol, high blood pressure or diabetes. It is approved for chronic use – that means it has been studied and approved for long-term weight control, similar to how we use medications for high cholesterol and for diabetes.
Contrave, otherwise known as NB32, is finally getting the opportunity to help individuals lose weight in the United States. The diet drug was rejected by the U.S. Food and Drug Administration (FDA) when it was first introduced in 2011 due to lack of solid data about heart risk. However, it is getting a second chance, as it successfully went through a preliminary stage in June 2014, and is expected to gain final approval in September 2014.
The New Year is here now, and I wanted to take a moment and share with you exciting updates for Denver residents regarding medical weight loss programs and medications for 2013. As we all know, 2012 was a very important year for medical weight loss centers around the country for several reasons including:
This is huge news for the medical weight loss community! For the first time in over 13 years, individuals needing help with life-long weight control have a new, clinically proven, scientifically valid treatment. Clinical trials lasting 2 years have demonstrated very good weight loss with Qsymia, averaging over 10%, with many patients losing 11 to 14% of their body weight (some lose substantially more than this).
After a 13 year hiatus, 2012 is an exciting year for obesity treatment. Hot on the heals of approving Belviq for obesity treatment, today the FDA approved another drug, Qsymia (formerly called Qnexa). This is exciting for a lot of…
After more than a decade with no new medications to treat obesity, today the FDA approved the obesity drug Lorcaserin, to be marketed later this year as Belviq. In clinical trials, the drug helped individuals lose an average of 5.7%…
